Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

A high-yielding dividend whitethorn dependable large for investors, but it tin beryllium a double-edged sword: erstwhile it's excessively high, investors commencement to interest astir its safety. That's a large portion of the crushed wherefore Pfizer (NYSE: PFE), whose 7.1% output is good supra the S&P 500 mean of conscionable 1.1%, isn't capable to gully successful investors; galore are disquieted the dividend is owed for a cut.

Not lone is Pfizer's dividend acold supra average, but it is present besides the highest output successful the full S&P 500. Is this a informing motion for investors that the dividend whitethorn beryllium chopped successful the adjacent future, oregon could Pfizer beryllium to beryllium an underrated income banal to bargain close now?

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Pfizer's output has been volatile successful caller years

A precocious output tin beryllium concerning, but that unsocial doesn't marque it risky. Similarly, conscionable due to the fact that a output is debased doesn't mean it's sustainable, either. The output tin fluctuate importantly due to the fact that it is tied to the stock price. When a banal is rising, its output falls due to the fact that it costs much to unafraid the aforesaid level of dividend income. And erstwhile it falls, arsenic has been the lawsuit with Pfizer's banal successful caller years, the output tin emergence significantly.

If Pfizer posts beardown net numbers successful its upcoming quarterly results, issues promising guidance, oregon there's affirmative quality astir 1 of its drugs, its stock terms could instrumentality off, and conscionable similar that, the output could travel down.

There is, however, immoderate hazard with the dividend due to the fact that Pfizer's net haven't been each that beardown successful caller quarters. During the archetypal 3 months of the year, the company's diluted per-share nett was $0.47, not overmuch higher than its quarterly dividend complaint -- $0.43. There's not overmuch of a buffer there, and investors whitethorn besides beryllium acrophobic astir its semipermanent future, arsenic the pharma institution deals with patent cliffs and navigates a challenging people ahead, which could spot its income (and profits) driblet successful the future.

Is Pfizer's banal worthy buying?

Pfizer's dividend whitethorn look shaky, but the bully quality is the company's net aren't successful atrocious shape, and it's successful the midst of restructuring and cutting costs, which should springiness it much breathing country successful the future. It has besides acquired companies that could unlock much maturation opportunities down the road.

While this whitethorn not beryllium the benignant of banal investors tin simply bargain and forget, Pfizer whitethorn beryllium a bully enactment for income investors consenting to show it closely. As of now, the dividend inactive looks safe, and this could beryllium an underrated enactment to consider, particularly fixed its debased valuation, arsenic the banal trades astatine conscionable 8 times its estimated aboriginal earnings, based connected expert expectations.